Abstract
Novel sensing technologies for liquid biopsies offer promising prospects for the early detection of metabolic conditions through omics techniques. Indeed, high-field nuclear magnetic resonance (NMR) facilities are routinely used for metabolomics investigations on a range of biofluids in order to rapidly recognise unusual metabolic patterns in patients suffering from a range of diseases. However, these techniques are restricted by the prohibitively large size and cost of such facilities, suggesting a possible role for smaller, low-field NMR instruments in biofluid analysis. Herein we describe selected biomolecule validation on a low-field benchtop NMR spectrometer (60 MHz), and present an associated protocol for the analysis of biofluids on compact NMR instruments. We successfully detect common markers of diabetic control at low-to-medium concentrations through optimised experiments, including α-glucose (≤2.8 mmol/L) and acetone (25 µmol/L), and additionally in readily accessible biofluids, particularly human urine. We present a combined protocol for the analysis of these biofluids with low-field NMR spectrometers for metabolomics applications, and offer a perspective on the future of this technique appealing to ‘point-of-care’ applications.
Highlights
Recognised as a powerful tool in translational medicine, the principles of metabolomics were arguably first described by ancient Chinese scholars, who used ants to evaluate the glucose level in the urine of diabetic patients [1]
We describe a complete procedural development for the analysis of biofluids by LF nuclear magnetic resonance (NMR) analysis, including validation and quantification experiments, experimental guidelines, and metabolomics data analysis, and these are experimentally demonstrated by an appropriate example-based in the area of type 2 diabetes
This analysis found that there were very highly significant differences between participants (p < 10−4), as expected; that between methods/techniques was barely statistically significant, and the only difference found between these four form of analyses using further analysis by Tukey’s highest significant difference (HSD) test, was that between 400 MHz 1H NMR-determined glucose levels and those obtained from the above dipstick approach, the latter being significantly greater than the former (p = 0.033)
Summary
Recognised as a powerful tool in translational medicine, the principles of metabolomics were arguably first described by ancient Chinese scholars, who used ants to evaluate the glucose level in the urine of diabetic patients [1]. MS and NMR are both considered standard techniques for metabolomics and metabonomics studies [19], this investigation will focus on the latter, and low-field (LF) compact, or mobile, benchtop NMR facilities These instruments operate at frequencies below 100 MHz, and are based on permanent magnets as opposed to the large, HF superconducting ones commonly found in analytical characterisation suites [20]. These facilities operating at LF suffer from the same issues of sensitivity which plagued early designs of NMR spectrometers [21]; with the employment of approaches such as solvent suppression [22] and magnet arrays [23], it is possible to simultaneously observe and monitor 20 or more metabolites in human saliva and urine at LF, as demonstrated here for the first time. We describe a complete procedural development for the analysis of biofluids by LF NMR analysis, including validation and quantification experiments, experimental guidelines, and metabolomics data analysis, and these are experimentally demonstrated by an appropriate example-based in the area of type 2 diabetes
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
